-
1 Comment
China Regenerative Medicine International Limited is currently in a long term downtrend where the price is trading 2.8% below its 200 day moving average.
From a valuation standpoint, the stock is 93.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.1.
China Regenerative Medicine International Limited's total revenue rose by 389.9% to $62M since the same quarter in the previous year.
Its net income has increased by 28.8% to $-222M since the same quarter in the previous year.
Finally, its free cash flow fell by 1122.6% to $-285M since the same quarter in the previous year.
Based on the above factors, China Regenerative Medicine International Limited gets an overall score of 3/5.
| ISIN | KYG2129W1125 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | HK |
| CurrencyCode | HKD |
| Beta | 1.23 |
|---|---|
| Market Cap | 110M |
| Target Price | None |
| PE Ratio | 6.0 |
| Dividend Yield | None |
China Regenerative Medicine International Limited, an investment holding company, engages in the provision of healthcare products and services in Hong Kong and the People's Republic of China. It operates through Aesthetic Medical and Beauty Services; and Medical Services segments. The company offers medical beauty products and services; and medical products and services. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Tsim Sha Tsui, Hong Kong.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 8158.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
